Dyne Therapeutics, Inc. reported a net loss of $446.2 million for the year ended December 31, 2025, compared to a net loss of $317.4 million for the previous year. The increased loss was primarily driven by higher research and development expenses, which totaled $398.3 million in 2025, up from $281.4 million in 2024. General and administrative expenses also increased, reaching $69.9 million compared to $62.5 million in the prior year. These increases were partially offset by higher interest income, which rose to $29.9 million from $26.9 million, and a decrease in other expenses, net, to $1.7 million from $0.5 million.
The company's research and development expenses were primarily focused on its key product candidates. Expenses related to z-rostudirsen (DMD) increased to $99.0 million, while z-basivarsen (DM1) expenses rose significantly to $145.1 million. Unallocated research and development expenses, including platform development, personnel, and facility-related costs, also contributed to the overall increase. The rise in personnel-related expenses was attributed to an increase in research and development headcount and higher stock-based compensation, while facility-related expenses increased due to the larger number of personnel.
Strategic developments during the year included the progression of z-rostudirsen and z-basivarsen towards potential regulatory submissions. Dyne anticipates submitting a BLA to the FDA for z-rostudirsen in the second quarter of 2026, with a potential U.S. launch in the first quarter of 2027, assuming priority review and approval. A Phase 3 clinical trial for z-rostudirsen is planned for the second quarter of 2026. For z-basivarsen, a BLA submission is targeted for early in the third quarter of 2027, with a potential U.S. launch in the first quarter of 2028, contingent on favorable data and FDA approval. A Phase 3 trial for z-basivarsen is planned for March 2026.
Key operational developments included the advancement of DYNE-302 (FSHD) and DYNE-401 (Pompe) programs, with DYNE-302 progressing towards clinical development. As of February 27, 2026, Dyne Therapeutics had 258 full-time employees, with 168 dedicated to research and development. The company's cash, cash equivalents, and marketable securities totaled $1.1 billion as of December 31, 2025, which is expected to fund operations into the first quarter of 2028. In June 2025, Dyne entered into a Loan Agreement with Hercules Capital, Inc., providing for term loans up to $275.0 million, with $100.0 million funded initially and an additional $50.0 million funded in December 2025.
Looking ahead, Dyne Therapeutics plans to continue advancing its pipeline, expanding its FORCE platform, and selectively entering into strategic collaborations. The company aims to build a sustainable leadership position in neuromuscular diseases, maintaining a strong connection with patients, caregivers, the research community, and physicians. However, the company acknowledges the need for substantial additional funding and the potential risks associated with clinical trials, competition, and regulatory approvals.
About Dyne Therapeutics, Inc.
Dyne Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for neuromuscular and genetic muscle diseases. Utilizing its proprietary FORCE platform, it creates conjugates of antibodies, linkers, and payloads—such as oligonucleotides and enzymes—to deliver disease-modifying treatments to muscle tissue and the CNS. Its portfolio includes therapies for DM1, DMD, FSHD, and Pompe disease, focusing on genetic targets with high unmet medical needs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.